| Date | Title | Description |
| 24.05.2025 | Access Denied | - |
| 19.05.2025 | Boosted by defense and Starlink, Orca AI pulls in $72.5M for its autonomous shipping platform | - |
| 31.01.2025 | Rad AI Closes $60M Series C to Further Solidify Leadership in Healthcare Generative AI | - |
| 04.12.2024 | Rapidly Growing Radiology AI Company, Rad AI, Strikes Partnership With Google Cloud | - |
| 04.12.2024 | OSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues | - |
| 25.11.2024 | Autonomous shipping startup Orca AI tops up with $23M led by OCV Partners and MizMaa Ventures | - |
| 25.11.2024 | TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline | - |
| 13.05.2024 | ByHeart Announces $95M in New Financing On The Heels of Rapid Growth and the Completion of its End-to-End Manufacturing, Furthering its Commitment to Transforming the Infant Formula Industry | With the addition of two new production facilities in Oregon and Iowa, ByHeart is now positioned to triple its supply capacity to support families nationwide
NEW YORK, May 13, 2024 /PRNewswire/ — ByHeart, the next-generation infant nutritio... |
| 07.05.2024 | Rad AI Closes $50 Million to Empower Physicians with AI |
SAN FRANCISCO, May 7, 2024 /PRNewswire/ — Rad AI, a leader in generative AI for healthcare, today announced it raised $50 million in Series B financing. The round was led by Khosla Ventures, with participation from WiL (World Innovation La... |
| 11.04.2024 | NorthStandard, Leading Maritime Insurer, Partners with Orca AI to Offer Safety Benefits of Situational Awareness Platform |
NorthStandard and Orca AI have entered an exclusive partnership that will see the global marine insurer encourage its members to adopt Orca AI’s market-leading automated situational awareness solution.
Orca AI’s situational awareness platf... |
| 13.04.2023 | TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics | TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug ... |
| 25.01.2023 | ByHeart Acquires Additional Domestic Infant Formula Manufacturing Facility Tripling its Supply Capacity and Continuing to Fortify Formula Production in the U.S. | NEW YORK, Jan. 25, 2023/ — Today, ByHeart announces the acquisition of an additional manufacturing facility that will enable the next-generation baby nutrition company to scale production capacity of its breakthrough infant formula and incr... |
| 05.01.2023 | ByHeart To Acquire Packaging Company Cascadia Nutrition | - |
| 22.11.2022 | Rad AI Completes Acquisition of Equium Intelligence, Further Enhancing Radiologist-Led Leadership Team | |
| 17.10.2022 | Ossio Raises $38.5M Series C to fuel its growth in the orthopedic space | |
| 23.03.2022 | ByHeart Announces the Launch of its Groundbreaking Infant Formula, Becoming the Only New Infant Formula Brand in Decades to Rewrite the Recipe From Scratch | |
| 12.01.2022 | Ockam Raises $12.5m Series A to Build a Remote-First, High-Performance Team | - |
| 10.11.2021 | Rad AI Closes $25 Million Series A to Transform Radiology Workflow by Harnessing the Power of Artificial Intelligence | |
| 09.11.2021 | SafeBreach Closes $53.5 Million Series D in New Funding to Fuel Momentum | - |
| 28.10.2021 | ByHeart, the First and Only Infant Formula Company in the US to Receive the Clean Label Project Purity Award | Congratulations to our portfolio company ByHeart on being the first and only infant formula company in the US to receive the “Clean Label Project Purity Award” certification from the Clean Label Project. |
| 26.10.2021 | General Partner Chris Bostick Named One of Biocom California’s Ten Life Science Trailblazers Under 40 for 2021 | OCV congratulates Dr. Chris Bostick on receiving the Biocom Life Science Catalyst Award. |
| 23.08.2021 | OCV Promotes Dr. Chris Bostick to General Partner | OCV Partners (“OCV”) announced today that Dr. Chris Bostick has been promoted to General Partner. |
| 26.07.2021 | ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints | ByHeart – the only new entrant to the US market to build its infant formula recipe entirely from scratch – achieves all of its clinical trial endpoints in the largest and most comprehensive clinical trial from a new infant formula brand in ... |
| 19.07.2021 | Invoice2go, an OCV portfolio company, to be acquired by Bill.com (NYSE: BILL) for $625 Million | |
| 02.06.2021 | ByHeart Completes Largest US Clinical Trial for a New Infant Formula Brand in the Last 25 Years Supporting their Innovation in Baby Nutrition | |
| 21.04.2021 | Orca AI, which puts computer vision onto cargo ships, raises $13M Series A funding | |
| 18.03.2021 | Finch Therapeutics Announces Pricing of Upsized Initial Public Offering | SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop ... |
| 20.10.2020 | Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares | CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorde... |
| 19.10.2020 | OSSIO Awarded FDA 510(k) Clearance for OSSIOfiber® Compression Screw Portfolio | |
| 29.09.2020 | OCV Partners Assist Portfolio Company Social Native in Acquiring Olapic to Create Next-Gen Creative Optimization Platform | LOS ANGELES–(BUSINESS WIRE)–Social Native, a marketplace technology company that empowers marketers to source and optimize visual content to improve brand awareness and performance, announced today the acquisition of Olapic, a leading user-... |
| 17.09.2020 | OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs | Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today an oversubscribed $90 million Series D financing. |
| 15.04.2020 | SafeBreach Raises $19 Million to Expand Channels, Accelerate Product Development | Sunnyvale, CA – April 15, 2020 — SafeBreach, provider of the leading breach-and-attack simulation (BAS) platform to validate security controls, visualize security risk and prioritize remediations, today announced that it has secured $19 mil... |
| 14.04.2020 | OCV Partners Co-leads By Heart’s $70M Series A Financing Ahead of First Product Launch in 2021 | NEW YORK, April 14, 2020 (Newswire.com) — ByHeart, a company focused on the evolution of one of our most fundamental nutrition markets – infant & baby – announced the recent closing of $70 million in Series A funding led by Polaris Part... |
| 12.03.2020 | OSSIO Receives FDA 510(k) Clearance for OSSIOfiber® Hammertoe Fixation System | WOBURN, Mass — OSSIO, Inc., an orthopedic fixation company, today announced that its OSSIOfiber® Hammertoe Fixation System has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment an... |
| 08.01.2020 | Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection | Somerville, MA (January 8, 2020) — Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome therapeutics company, announced today that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical... |
| 22.08.2019 | Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas | Somerville, MA (August 22, 2019) — Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Pa... |
| 14.08.2019 | Museum of Ice Cream Founders Launch Figure8 with Series A to Transform How Millennials and Gen-Z Connect With Spaces and Each Other | New York, NY (August 14, 2019) — Founders of Museum of Ice Cream, Maryellis Bunn and Manish Vora, launch Figure8, an experience-first development company. Figure8, now parent company of Museum of Ice Cream, completed its first close of a $4... |
| 11.03.2019 | OSSIO Secures $22 Million in Financing | WOBURN, MA., March 11, 2019 — OSSIO, an orthopedic fixation company, today announced the closing of $22 million in equity financings led by OCV Partners, a Los Angeles based venture capital firm, with continued participation from existing i... |
| 11.09.2018 | Invoice2go Raises $10 Million, Attracting New and Existing Investors, and Hemi Zucker from OCV Partners to join the Board of Directors | REDWOOD CITY, Calif., Sept 11, 2018 — Invoice2go announces it has closed a $10 million equity round led by OCV Partners, with additional participation from existing investors Accel and Ribbit Capital. Hemi Zucker of OCV Partners joins the I... |
| 26.06.2018 | Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs | DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was... |
| 01.01.2018 | Hemi Zucker to Join OCV Management as Managing Principal | LOS ANGELES – OCV Management LLC (“OCV”), a technology investor based in Los Angeles, announced today that Nehemia (“Hemi”) Zucker will be joining the firm as Managing Principal starting on January 1, 2018. Until such date, Hemi will contin... |
